BridgeBio Pharma Inc [BBIO] stock prices are up 8.84% to $25.48 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBIO shares have gain 6.88% over the last week, with a monthly amount drifted -0.59%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On September 04, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $46 on the stock. BMO Capital Markets initiated its recommendation with a Market Perform and recommended $37 as its price target on January 31, 2024. Wells Fargo started tracking with a Overweight rating for this stock on December 08, 2023, and assigned it a price target of $58. In a note dated December 08, 2023, Wells Fargo initiated an Overweight rating.
The stock price of BridgeBio Pharma Inc [BBIO] has been fluctuating between $21.62 and $44.32 over the past year. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. BridgeBio Pharma Inc [NASDAQ: BBIO] shares were valued at $25.48 at the most recent close of the market. An investor can expect a potential return of 76.61% based on the average BBIO price forecast.
Analyzing the BBIO fundamentals
The BridgeBio Pharma Inc [NASDAQ:BBIO] reported sales of 219.12M for trailing twelve months, representing a surge of 32.11%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -2.3%, Pretax Profit Margin comes in at -2.09%, and Net Profit Margin reading is -2.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is 0.39 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.58.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.01 points at the first support level, and at 22.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.30, and for the 2nd resistance point, it is at 27.11.
Ratios To Look Out For
It’s worth pointing out that BridgeBio Pharma Inc [NASDAQ:BBIO]’s Current Ratio is 4.59. As well, the Quick Ratio is 4.59, while the Cash Ratio is 4.07. Considering the valuation of this stock, the price to sales ratio is 23.80.
Transactions by insiders
Recent insider trading involved KKR Genetic Disorder L.P., 10% Owner, that happened on Sep 13 ’24 when 5.8 million shares were sold. Affiliate, KKR Genetic Disorder L.P. completed a deal on Sep 13 ’24 to buy 5.8 million shares. Meanwhile, Chief Executive Officer Kumar Neil sold 27389.0 shares on Aug 19 ’24.
